Full text is available at the source.
Abstract
There is a significant lack of comprehensive studies on the interactions between glucagon-like peptide-1 receptor agonists and hormonal contraception.
- Limited existing research evaluates the potential pharmacokinetic and pharmacodynamic interactions between these two drug classes.
- Knowledge gaps remain regarding how glucagon-like peptide-1 receptor agonists may affect the efficacy and safety of hormonal contraceptives.
- Potential interactions could occur across various areas of the female reproductive tract.
- Incorporating contraceptive counseling into care is suggested when starting glucagon-like peptide-1 receptor agonists.
Simplified